BioCryst Pharmaceuticals

What BioCryst Pharmaceuticals does

BioCryst Pharmaceuticals is a commercial-stage biotechnology company headquartered in Durham, North Carolina, founded in 1986. The company discovers, develops, and commercializes small-molecule and injectable protein therapeutics for rare diseases, using a proprietary structure-guided drug design platform that integrates X-ray crystallography, cryo-EM, computer modeling, virtual screening, and molecular dynamics simulations to design molecules atom-by-atom for optimal target binding. Its commercial portfolio is anchored by ORLADEYO (berotralstat), the first and only FDA-approved oral plasma kallikrein inhibitor for prophylactic treatment of hereditary angioedema in patients aged 2 and older, and RAPIVAB (peramivir), an injectable neuraminidase inhibitor for acute uncomplicated influenza. The pipeline includes navenibart (Phase 3 monoclonal antibody for HAE, acquired through the January 2026 Astria Therapeutics transaction), BCX17725 (Phase 1 KLK5 inhibitor for Netherton syndrome), and STAR-0310 (Phase 1 anti-OX40 antibody for atopic dermatitis).

BioCryst generates revenue primarily through direct US commercialization of ORLADEYO via a specialty sales force targeting allergists, immunologists, and specialty pharmacies, supplemented by international distribution and licensing partnerships (Neopharmed Gentili for Europe, plus regional distributors across MEA, LATAM, and APAC). ORLADEYO pricing is set at specialty rare-disease levels ($48,487.92 per 28-day pack as of January 2026), reflecting its orphan indication status and limited oral competition. FY2025 revenue reached $874.8M (94% YoY) with ORLADEYO contributing $601.8M (+38% YoY) and the European ORLADEYO divestiture adding ~$250M; the company achieved its first net income of $263.86M in 2025. The 2026 European licensing deal for navenibart (up to $345M in upfront and milestones plus 18-30% tiered royalties) and the Astria Therapeutics acquisition materially expand both the pipeline and international commercial footprint. The customer base consists of patients with rare genetic conditions (HAE prevalence 1:10,000-1:50,000, plus the much smaller Netherton syndrome population), making the therapeutic categories commercially constrained but defensible through regulatory exclusivity and physician/patient persistence.

Name

BioCryst Pharmaceuticals

Legal name

BioCryst Pharmaceuticals, Inc.

Website

https://biocryst.com

Company type

Public

Founded year

1986

Operating status

Operating

Headcount range

501–1,000 employees

Short description

BioCryst Pharmaceuticals is a commercial-stage biotech that discovers and commercializes small-molecule and injectable protein therapeutics for rare diseases, anchored by ORLADEYO, the first oral prophylactic therapy for hereditary angioedema, serving HAE patients globally through direct US sales and international licensing partnerships.

Ownership category

akta.pro rank

Product category

Rare Disease Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industries

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Rare disease therapeutics
• Hereditary angioedema treatment
• Plasma kallikrein inhibitors
• Structure-guided drug design
• Oral prophylactic therapies

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. ORLADEYO (berotralstat) Sales: Primary revenue driver from sales of ORLADEYO, an oral prophylactic therapy for hereditary angioedema. Generated approximately $601.8 million in full-year 2025 revenue, up 38% year-over-year. Q4 2025 sales of approximately $151 million. Q1 2026 revenue of $148.3 million representing 11% year-over-year growth. The company projects 2026 revenue guidance of $625-645 million.
2. European Licensing - Navenibart: Licensing revenue from Neopharmed Gentili for European commercial rights to navenibart. Received $70 million upfront with potential milestone payments up to $275 million and tiered royalties of 18-30% on net sales.
3. European ORLADEYO Divestiture: In 2025, BioCryst sold its European ORLADEYO business to Neopharmed Gentili for approximately $250 million upfront plus potential additional considerations, contributing to the 94% revenue increase to $874.8 million in 2025.
4. RAPIVAB (peramivir injection): Revenue from sales of RAPIVAB, an influenza treatment. Secondary product alongside the primary ORLADEYO franchise.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops, and commercializes small-molecule and injectable protein therapeutics for rare diseases. Its marketed products include ORLADEYO (berotralstat), the first and only targeted oral plasma kallikrein inhibitor approved for prophylaxis of hereditary angioedema (HAE) in patients aged 2 and older, and RAPIVAB (peramivir injection), a neuraminidase inhibitor for acute uncomplicated influenza. The pipeline includes navenibart (Phase 3 monoclonal antibody for HAE), BCX17725 (KLK5 inhibitor for Netherton syndrome), and STAR-0310 (anti-OX40 antibody for atopic dermatitis).

Product overview

BioCryst Pharmaceuticals is a commercial-stage biotech company with a portfolio of approved and pipeline therapeutics for rare diseases. The core commercial products include ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor for hereditary angioedema (HAE) available for adults and children aged 2+, and RAPIVAB (peramivir), an influenza treatment. The pipeline includes navenibart (Phase 3 monoclonal antibody for HAE acquired from Astria Therapeutics), BCX17725 (Phase 1 for Netherton syndrome), and STAR-0310 (Phase 1 for atopic dermatitis, also from Astria acquisition). The company uses structure-guided drug design to develop oral small-molecule and injectable protein therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• ORLADEYO (berotralstat) An oral plasma kallikrein inhibitor indicated for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older; also available as an oral pellet formulation approved for pediatric patients aged 2 to under 12 years. It is the first and only targeted oral prophylactic therapy for HAE.
• RAPIVAB (peramivir injection) An influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than two days.
• Navenibart (STAR-0215) A monoclonal antibody plasma kallikrein inhibitor in Phase 3 development (ALPHA-ORBIT) for prophylaxis of hereditary angioedema, offering potential long-acting therapeutic option with every-three and every-six month dosing. Acquired through the January 2026 Astria Therapeutics acquisition.
• BCX17725 A KLK5 inhibitor protein therapeutic in Phase 1 development for the potential treatment of Netherton syndrome, a rare genetic skin disorder with no currently approved treatments.
• STAR-0310 An anti-OX40 half-life extended monoclonal antibody in Phase 1 development for the potential treatment of atopic dermatitis. Acquired through the Astria Therapeutics transaction.

Quantifiable outcome

• ORLADEYO reduced median HAE attack rates from 0.691 to 0.169 per month in pediatric patients aged 2 to <12 years over 48 weeks of treatment
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Neopharmed GentilicoreChannel Partner/ Reseller/ Distributor · 1 May 2026Licensing agreement granting Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart across Europe. BioCryst receives $70 million upfront, up to $275 million in regulatory and sales milestone payments, and tiered royalties of 18% to 30% on net sales. Builds on prior 2025 transaction where Neopharmed Gentili acquired BioCryst's European ORLADEYO business.
• Astria TherapeuticscoreStrategic or Co-development Partner · 23 January 2026BioCryst completed acquisition of Astria Therapeutics for approximately $700 million in January 2026, financed through cash on hand, a $396.6 million Blackstone financing facility, and issuance of 37.3 million BioCryst shares. The acquisition added navenibart (Phase 3 plasma kallikrein inhibitor for HAE) and early-stage atopic dermatitis program STAR-0310 to BioCryst's portfolio. Astria's CEO Jill C. Milne joined BioCryst's Board of Directors.
• Neopharmed GentilicoreChannel Partner/ Reseller/ Distributor · 1 July 2025Sale of European ORLADEYO business to Neopharmed Gentili for approximately $250 million upfront with potential additional milestone considerations. Transaction completed October 2025.
• Neopharm GroupminorChannel Partner/ Reseller/ Distributor · 1 January 2025International distribution partnership for commercialization of ORLADEYO outside the United States.
• NewBridge PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 1 January 2025International distribution partnership for commercialization of ORLADEYO outside the United States.
• Pint PharmaminorChannel Partner/ Reseller/ Distributor · 1 January 2025International distribution partnership for commercialization of ORLADEYO outside the United States.
• Swixx BioPharmaminorChannel Partner/ Reseller/ Distributor · 1 January 2025International distribution partnership for commercialization of ORLADEYO outside the United States.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Takeda Pharmaceutical: Takeda markets Takhzyzo (lanadelumab), a leading HAE prophylactic therapy and the most direct competitor to BioCryst's ORLADEYO and the navenibart pipeline asset.
• Pharming Group: Pharming markets RUCONEST (C1 esterase inhibitor) for acute HAE attacks and is developing leniolisib, directly competing in the HAE therapeutic space and in rare immunology.
• CSL Behring: CSL Behring markets HAEGARDA, a subcutaneous C1 esterase inhibitor widely used for HAE prophylaxis, directly competing with ORLADEYO for HAE share.
• KalVista Pharmaceuticals: KalVista is developing oral plasma kallikrein inhibitors for HAE, making it a direct pipeline competitor to ORLADEYO and to BioCryst's HAE franchise.

Broad incumbents

• Ionis Pharmaceuticals: Ionis is a leading RNA-targeted rare disease company with a broad specialty/rare disease pipeline, comparable to BioCryst's structure-guided approach and rare disease focus.
• Alnylam Pharmaceuticals: Alnylam is a commercial-stage RNAi therapeutics company with rare disease franchises and global partnerships, comparable in commercial maturity, royalty/licensing model, and rare disease focus.
• Vertex Pharmaceuticals: Vertex is a profitable rare disease-focused biopharma with specialty commercial capabilities, comparable as a profitable, focused rare disease commercial-stage company with active pipeline expansion.
• Regeneron Pharmaceuticals: Regeneron has a large specialty/rare disease franchise and monoclonal antibody expertise, relevant to BioCryst as it advances navenibart, a plasma kallikrein mAb, in HAE.
• BioMarin Pharmaceutical: BioMarin is a commercial-stage rare disease company with a similar focus on small patient populations and specialty pricing, comparable in business model and orphan disease focus.

Emerging players

• Intellia Therapeutics: Intellia is an early- to mid-stage genetic medicine company targeting rare diseases; relevant as an emerging rare disease therapeutic peer with a technology platform approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/BioCrystPharma
• Facebookfacebook.com/biocrystpharma
• LinkedInlinkedin.com/company/biocryst-pharmaceuticals
• Instagraminstagram.com/biocrystpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries4 records

Funding overview

Funding rounds19 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCryst Pharmaceuticals